380 related articles for article (PubMed ID: 31103721)
1. Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort.
Blazevski A; Scheltema MJ; Yuen B; Masand N; Nguyen TV; Delprado W; Shnier R; Haynes AM; Cusick T; Thompson J; Stricker P
Eur Urol Oncol; 2020 Jun; 3(3):283-290. PubMed ID: 31103721
[TBL] [Abstract][Full Text] [Related]
2. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.
Scheltema MJ; van den Bos W; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD
BJU Int; 2017 Nov; 120 Suppl 3():51-58. PubMed ID: 28834167
[TBL] [Abstract][Full Text] [Related]
3. Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancer.
Scheltema MJ; Geboers B; Blazevski A; Doan P; Katelaris A; Agrawal S; Barreto D; Shnier R; Delprado W; Thompson JE; Stricker PD
BJU Int; 2023 Jun; 131 Suppl 4():6-13. PubMed ID: 36495481
[TBL] [Abstract][Full Text] [Related]
4. Focal therapy for prostate cancer with irreversible electroporation: Oncological and functional results of a single institution study.
Yaxley WJ; Gianduzzo T; Kua B; Oxford R; Yaxley JW
Investig Clin Urol; 2022 May; 63(3):285-293. PubMed ID: 35534217
[TBL] [Abstract][Full Text] [Related]
5. Focal irreversible electroporation as primary treatment for localized prostate cancer.
van den Bos W; Scheltema MJ; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD
BJU Int; 2018 May; 121(5):716-724. PubMed ID: 28796935
[TBL] [Abstract][Full Text] [Related]
6. Median 4-year outcomes of salvage irreversible electroporation for localized radio-recurrent prostate cancer.
Geboers B; Scheltema MJ; Blazevski A; Katelaris A; Doan P; Ali I; Agrawal S; Barreto D; Matthews J; Haynes AM; Delprado W; Shnier R; Thompson JE; Stricker PD
BJU Int; 2023 Jun; 131 Suppl 4():14-22. PubMed ID: 36594205
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Irreversible Electroporation-A Multicenter Validation Study.
Geboers B; Gondoputro W; Thompson JE; Reesink DJ; van Riel LAMJG; Zhang D; Blazevski A; Doan P; Agrawal S; Matthews J; Haynes AM; Liu Z; Delprado W; Shnier R; de Reijke TM; Lawrentschuk N; Stijns PEF; Yaxley JW; Scheltema MJ; Stricker PD
Eur Urol Focus; 2022 Nov; 8(6):1591-1598. PubMed ID: 35577751
[TBL] [Abstract][Full Text] [Related]
8. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer.
Guillaumier S; Peters M; Arya M; Afzal N; Charman S; Dudderidge T; Hosking-Jervis F; Hindley RG; Lewi H; McCartan N; Moore CM; Nigam R; Ogden C; Persad R; Shah K; van der Meulen J; Virdi J; Winkler M; Emberton M; Ahmed HU
Eur Urol; 2018 Oct; 74(4):422-429. PubMed ID: 29960750
[TBL] [Abstract][Full Text] [Related]
9. Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE).
Blazevski A; Amin A; Scheltema MJ; Balakrishnan A; Haynes AM; Barreto D; Cusick T; Thompson J; Stricker PD
World J Urol; 2021 Apr; 39(4):1107-1114. PubMed ID: 32488359
[TBL] [Abstract][Full Text] [Related]
10. Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial.
Scheltema MJ; van den Bos W; de Bruin DM; Wijkstra H; Laguna MP; de Reijke TM; de la Rosette JJ
BMC Cancer; 2016 May; 16():299. PubMed ID: 27150293
[TBL] [Abstract][Full Text] [Related]
11. Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation.
Scheltema MJ; Chang JI; van den Bos W; Böhm M; Delprado W; Gielchinsky I; de Reijke TM; de la Rosette JJ; Siriwardana AR; Shnier R; Stricker PD
Eur Urol Focus; 2019 Jul; 5(4):585-591. PubMed ID: 29102671
[TBL] [Abstract][Full Text] [Related]
12. Salvage irreversible electroporation for radio-recurrent prostate cancer - the prospective FIRE trial.
Blazevski A; Geboers B; Scheltema MJ; Gondoputro W; Doan P; Katelaris A; Agrawal S; Baretto D; Matthews J; Haynes AM; Delprado W; Shnier R; van den Bos W; Thompson JE; Lawrentschuk N; Stricker PD
BJU Int; 2023 Jun; 131 Suppl 4():23-31. PubMed ID: 36495482
[TBL] [Abstract][Full Text] [Related]
13. Effect of Focal vs Extended Irreversible Electroporation for the Ablation of Localized Low- or Intermediate-Risk Prostate Cancer on Early Oncological Control: A Randomized Clinical Trial.
Zhang K; Teoh J; Laguna P; Dominguez-Escrig J; Barret E; Ramon-Borja JC; Muir G; Bohr J; de Reijke TM; Pelechano Gómez P; Ng CF; Sanchez-Salas R; de la Rosette J
JAMA Surg; 2023 Apr; 158(4):343-349. PubMed ID: 36723911
[TBL] [Abstract][Full Text] [Related]
14. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry.
Shah TT; Peters M; Eldred-Evans D; Miah S; Yap T; Faure-Walker NA; Hosking-Jervis F; Thomas B; Dudderidge T; Hindley RG; McCracken S; Greene D; Nigam R; Valerio M; Minhas S; Winkler M; Arya M; Ahmed HU
Eur Urol; 2019 Jul; 76(1):98-105. PubMed ID: 30638633
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of salvage radical prostatectomy after initial irreversible electroporation treatment for recurrent prostate cancer.
van Riel LAMJG; Geboers B; Kabaktepe E; Blazevski A; Reesink DJ; Stijns P; Stricker PD; Casanova J; Dominguez-Escrig JL; de Reijke TM; Scheltema MJ; Oddens JR
BJU Int; 2022 Nov; 130(5):611-618. PubMed ID: 35474600
[TBL] [Abstract][Full Text] [Related]
16. Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes.
Collettini F; Enders J; Stephan C; Fischer T; Baur ADJ; Penzkofer T; Busch J; Hamm B; Gebauer B
Radiology; 2019 Jul; 292(1):250-257. PubMed ID: 31161973
[TBL] [Abstract][Full Text] [Related]
17. Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment.
Blazevski A; Scheltema MJ; Amin A; Thompson JE; Lawrentschuk N; Stricker PD
BJU Int; 2020 Mar; 125(3):369-378. PubMed ID: 31725935
[TBL] [Abstract][Full Text] [Related]
18. Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After Radiotherapy.
Shah TT; Kanthabalan A; Otieno M; Pavlou M; Omar R; Adeleke S; Giganti F; Brew-Graves C; Williams NR; Grierson J; Miah H; Emara A; Haroon A; Latifoltojar A; Sidhu H; Clemente J; Freeman A; Orczyk C; Nikapota A; Dudderidge T; Hindley RG; Virdi J; Arya M; Payne H; Mitra A; Bomanji J; Winkler M; Horan G; Moore CM; Emberton M; Punwani S; Ahmed HU
Eur Urol; 2022 Jun; 81(6):598-605. PubMed ID: 35370021
[TBL] [Abstract][Full Text] [Related]
19. Salvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes.
Blazevski A; Gondoputro W; Scheltema MJ; Amin A; Geboers B; Barreto D; Haynes AM; Shnier R; Delprado W; Agrawal S; Thompson JE; Stricker PD
BMC Urol; 2022 Mar; 22(1):28. PubMed ID: 35236338
[TBL] [Abstract][Full Text] [Related]
20. Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: a Prospective Development Study.
Ahmed HU; Dickinson L; Charman S; Weir S; McCartan N; Hindley RG; Freeman A; Kirkham AP; Sahu M; Scott R; Allen C; Van der Meulen J; Emberton M
Eur Urol; 2015 Dec; 68(6):927-36. PubMed ID: 25682339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
